(1-34) parathyroid hormone infusion acutely lowers fibroblast growth factor 23 concentrations in adult volunteers

Clinical Journal of the American Society of Nephrology

Volumn 7, Issue 1, 2012, Pages 139-145

  Gutiérrez, Orlando M ^a   Smith, Kelsey T ^a   Barchi Chung, Allison ^a   Patel, Neha M ^a   Isakova, Tamara ^a   Wolf, Myles ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,25 DIHYDROXYERGOCALCIFEROL; CALCIUM; CREATININE; FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE[1-34]; PHOSPHATE;

ADULT; ARTICLE; CALCIUM BLOOD LEVEL; CALCIUM URINE LEVEL; CAUCASIAN; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CREATININE URINE LEVEL; HUMAN; PHOSPHATE BLOOD LEVEL; PHOSPHATE URINE LEVEL; PROTEIN SECRETION; RACE; RACE DIFFERENCE; VITAMIN BLOOD LEVEL;

ADULT; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; MALE; MIDDLE AGED; PARATHYROID HORMONE; PHOSPHATES; VITAMIN D;

EID: 84863402820     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.06240611     Document Type: Article

References (30)

1. Liu S, Quarles LD: How fibroblast growth factor 23 works. J Am Soc Nephrol 18: 1637-1647, 2007
2. Evenepoel P, Meijers B, Viaene L, Bammens B, Claes K, Kuypers D, Vanderschueren D, Vanrenterghem Y: Fibroblast growth factor-23 in early chronic kidney disease: additional support in favor of a phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism. Clin J Am Soc Nephrol 5: 1268-1276, 2010
3. Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, Jüppner H, Wolf M: Fibroblast growth factor-23 mitigates hy-perphosphatemia but accentuates calcitriol deficiencyin chronic kidney disease. J Am Soc Nephrol 16: 2205-2215, 2005
4. Gutiérrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Jüppner H, Wolf M: Fibro-blast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359: 584-592, 2008
5. Jean G, Terrat JC, Vanel T, Hurot JM, Lorriaux C, Mayor B, Chazot C: High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol Dial Transplant 24: 2792-2796, 2009
6. Parker BD, Schurgers LJ, Brandenburg VM, Christenson RH, Vermeer C, Ketteler M, Shlipak MG, Whooley MA, Ix JH: The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: The Heart and Soul Study. Ann Intern Med 152: 640-648, 2010
7. Seiler S, Reichart B, Roth D, Seibert E, Fliser D, Heine GH: FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment. Nephrol Dial Transplant 25: 3983-3989, 2010
8. Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, Wahl P, Gutiérrez OM, Steigerwalt S, He J, Schwartz S, Lo J, Ojo A, Sondheimer J, Hsu CY, Lash J, Leonard M, Kusek JW, Feldman HI, Wolf M Chronic Renal Insufficiency Cohort (CRIC) Study Group: Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 305: 2432-2439, 2011
9. Quarles LD: Endocrine functions of bone in mineral metabolism regulation. J Clin Invest 118: 3820-3828, 2008
10. Lavi-Moshayoff V, Wasserman G, Meir T, Silver J, Naveh-Many T: PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: A bone parathyroid feedback loop. Am J Physiol Renal Physiol 299: F882-F889, 2010
11. Kawata T, Imanishi Y, Kobayashi K, Miki T, Arnold A, Inaba M, Nishizawa Y: Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism. J Am Soc Nephrol 18: 2683-2688, 2007
12. Lopez I, Rodriguez-Ortiz ME, Almaden Y, Guerrero F, Oca AM, Pineda C, Shalhoub V, Rodriguez M, Aguilera-Tejero E: Direct and indirect effects of parathyroid hormone on circulating levels of fi-broblast growth factor 23 in vivo. Kidney Int 80: 475-482, 2011
13. Liu S, Tang W, Zhou J, Stubbs JR, Luo Q, Pi M, Quarles LD: Fi-broblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 17: 1305-1315, 2006
14. Saji F, Shigematsu T, Sakaguchi T, Ohya M, Orita H, Maeda Y, Ooura M, Mima T, Negi S: Fibroblast growth factor 23 production in bone is directly regulated by 1alpha,25-dihydroxyvitaminD, but not PTH. Am J Physiol Renal Physiol 299: F1212-F1217, 2010
15. Samadfam R, Richard C, Nguyen-Yamamoto L, Bolivar I, Goltzman D: Bone formation regulates circulating concentrations of fibroblast growth factor 23. Endocrinology 150: 4835-4845, 2009
16. Burnett-Bowie SM, Henao MP, Dere ME, Lee H, Leder BZ: Effects of hPTH(1-34) infusion on circulating serum phosphate, 1,25-dihydroxyvitamin D, and FGF23 levels in healthy men. J Bone Miner Res 24: 1681-1685, 2009
17. Wesseling-Perry K, Harkins GC, Wang HJ, Elashoff R, Gales B, Horwitz MJ, Stewart AF, Jüppner H, Salusky IB: The calcemic response to continuous parathyroid hormone (PTH)(1-34) infusion in end-stage kidney disease varies according to bone turnover: A potential role for PTH(7-84). J Clin Endocrinol Metab 95: 2772-2780, 2010
18. Sridharan M, Cheung J, Moore AE, Frost ML, Fraser WD, Fogelman I, Hampson G: Circulating fibroblast growth factor-23 increases following intermittent parathyroid hormone (1-34) in postmenopausal osteoporosis: Association with biomarker of bone formation. Calcif Tissue Int 87: 398-405, 2010
19. McElduff A, Lissner D, Wilkinson M, Cornish C, Posen S: A 6-hour human parathyroid hormone (1-34) infusion protocol: Studies in normal and hypoparathyroid subjects. Calcif Tissue Int 41: 267-273, 1987
20. Gutiérrez OM, Isakova T, Smith K, Epstein M, Patel N, Wolf M: Racial differences in postprandial mineral ion handling in health and in chronic kidney disease. Nephrol Dial Transplant 25: 3970-3977, 2010
21. Cosman F, Morgan DC, Nieves JW, Shen V, Luckey MM, Dempster DW, Lindsay R, Parisien M: Resistance to bone re-sorbing effects of PTH in black women. J Bone Miner Res 12: 958-966, 1997
22. Cosman F, Shen V, Herrington B, Lindsay R: Response of the parathyroid gland to infusion of human parathyroid hormone-(1-34) [PTH-(1-34)]: Demonstration of suppression of endogenous secretion using immunoradiometric intact PTH-(1-84) assay. J Clin Endocrinol Metab 73: 1345-1351, 1991
23. Halloran BP, Lonergan ET, Portale AA: Aging and renal responsiveness to parathyroid hormone in healthy men. J Clin Endocrinol Metab 81: 2192-2197, 1996
24. Yeh KC, Kwan KC: A comparison of numerical integrating algorithms by trapezoidal, Lagrange, and spline approximation. J Pharmacokinet Biopharm 6: 79-98, 1978
25. Ito N, Fukumoto S, Takeuchi Y, Takeda S, Suzuki H, Yamashita T, Fujita T: Effect of acute changes of serum phosphate on fibroblast growth factor (FGF)23 levels in humans. J Bone Miner Metab 25: 419-422, 2007
26. Hock JM, Gera I: Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone. J Bone Miner Res 7: 65-72, 1992
27. Law WM, Heath H: Time- and dose-related biphasic effects of synthetic bovine parathyroid hormone fragment 1-34 on urinary cation excretion. J Clin Endocrinol Metab 58: 606-608, 1984
28. Vervloet MG, van Ittersum FJ, Büttler RM, Heijboer AC, Blankenstein MA, Ter Wee PM: Effects of dietary phosphate and calcium intake on fibroblast growth factor-23. Clin J Am Soc Nephrol 6: 383-389, 2011
29. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, Goetz R, Kuro-o M, Mohammadi M, Sirkis R, Naveh-Many T, Silver J: The parathyroid is a target organ for FGF23 in rats. J Clin Invest 117: 4003-4008, 2007
30. Krajisnik T, Björklund P, Marsell R, Ljunggren O, Akerström G, Jonsson KB, Westin G, Larsson TE: Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol 195: 125-131, 2007